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Abstract
Placement of a central venous catheter (CVC) is fundamental for the administration of chemotherapeutic
agents and supportive therapy for patients with acute myeloid leukemia (AML). We performed a single-center,
randomized trial comparing peripherally inserted central catheter (PICC)-related and centrally inserted central
catheter (CICC)-related complications. Among 93 randomized patients, PICC was safer than CICC, with a 36-
percentage point reduction in the complication rate, while maintaining effectiveness. We propose PICC as a
new frontline central vascular access option for patients with AML.
Background: The incidence of peripherally inserted central catheter (PICC)-related adverse events has been
uncertain in the setting of acute myeloid leukemia (AML) compared with the incidence of centrally inserted
central catheter (CICC) adverse events. Patients and Methods: We conducted a monocentric, randomized trial of
patients with previously untreated AML. Of the 93 patients, 46 had received a PICC and 47 had received a CICC as
frontline intravascular device. Thereafter, all patients underwent intensive chemotherapy for hematologic remission
induction. The primary endpoint was catheter-related (CR)-bloodstream infection (BSI) and venous thrombosis (VT)
rate. The secondary endpoints catheter malfunction, catheter removal, and patient overall survival. Results: The
CR-BSI and CR-VT rate in the PICC and CICC groups was 13% and 49%, respectively, with a difference of 36
percentage points (relative risk for CR-BSI or CR-VT, 0.266; P ¼ .0003). The CR-BSI incidence was 1.4 and 7.8 per
1000 catheters daily in the PICC and CICC groups, respectively. Among the CR thromboses, the symptomatic VT
rate was 2.1% in the PICC group and 10.6% in the CICC group. In the CICC group, 16 of the 47 patients (34%) had
the catheter removed for BSI (n ¼ 5), septic thrombophlebitis (n ¼ 4), VT (n ¼ 2), or malfunction (n ¼ 5) a median of 7
days after insertion. In the PICC group, only 6 of the 46 patients (13%) required catheter removal for VT (n ¼ 2) or
malfunction (n ¼ 4). At a median follow-up of 30 days, 6 patients in the CICC group died of CR complications versus
none of the patients in the PICC group (P ¼ .012). Using PICCs, the reduction in BSI and symptomatic VT decreased
mortality from CR infection and venous thromboembolism. In contrast, the CICC approach led to early catheter
removal mostly for difﬁcult-to-treat infectious pathogens. Conclusion: Our data have conﬁrmed that BSI and
symptomatic VT are the major complications affecting frontline central intravascular device-related morbidity in the
leukemia setting. The use of a PICC is safer than that of a CICC and maintains the effectiveness for patients with1Department of Advanced Biomedical Sciences
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The outcome for patients with acute myeloid leukemia (AML)
has improved greatly during the past 50 years.1 Despite regional
differences, the most commonly used induction regimen has
included cytarabine at a daily dose of 100 to 6000 mg/m2 for 4 to
10 days combined with 3 days of an anthracycline, such as doxo-
rubicin.1-4 These schedules result in complete remission rates of
60% to 80%, depending on patient age and the cytogenetic and
molecular features of the acute leukemia. However,  60% of
patients receiving cytarabine-based treatments will experience grade
3 and 4 hematologic and extrahematologic toxicities, requiring
maximal supportive care.1-4
Reliable intravascular access is extremely important for the treat-
ment of hematologic malignancies in critically ill patients. An
appropriate central venous catheter (CVC) will not only facilitate
administration of chemotherapeutic agents but will also provide a
route for hydration, blood derivate transfusions, antimicrobial
administration, and parenteral hyperalimentation.5,6 Previously, a
centrally inserted central catheter (CICC), implanted in the
cervicalethoracic area using a nontunneled or skin-tunneled device
for a short (30 days) or an intermediate term, respectively, was the
conventional venous access used for patients with cancer. Problems
have occurred after CICC insertion, especially in the case of acute
leukemia. Thromboses and infections are important complica-
tions.7,8 A 10% to 15% incidence of CICC-associated clinically
manifest venous thrombosis (VT) and a 30% to 70% incidence of
CICC-associated subclinical VT have been reported among patients
with AML.7 The pathogenesis of catheter infection can be secondary
to extraluminal or intraluminal contamination.5-8 The incidence of
CICC-associated blood stream infection (BSI) has ranged from 15%
to 30% in the setting of patients with acute leukemia with
chemotherapy-induced severe neutropenia.8 The infection of the
intravascular device has been most frequently caused by staphylo-
cocci,6,8 which can develop resistance to systemic antibiotics
(so-called multidrug-resistance strains) and become difﬁcult to
eradicate. In such cases, the risk of septic thrombophlebitis, massive
septic pulmonary emboli, and/or septic shock will be increased.5,6,8
Peripherally inserted central catheters (PICCs) have increasingly
been used for short-term to intermediate-term (<4 months) venous
access during the past few years for patients with cancer. This has
occurred for several reasons, including the number of uses (eg, drug
administration, transfusions, total parenteral nutrition, venous sam-
pling) and the proliferation of nurse led-dedicated teams.9 The results
from systematic reviews and/or meta-analyses have suggested that
PICCs might be associated with a greater rate of major adverse events
(ie, upper extremity VT and/or BSI) compared with CICCs, espe-
cially in the case of acute leukemia.9-11 Theoretically, these ﬁndings
were surprising because the use of PICCs might be safer than that ofnical Lymphoma, Myeloma & Leukemia Month 2019CICCs. First, the insertion of PICCs uses an easier method, with a
minor trauma at the implantation site compared with theCICCs.12,13
Second, the cutaneous area of the middle third of the upper arm
(where the PICC is implanted) contains quantitatively fewer micro-
organisms than the cervicalethoracic cutaneous area (where the
CICC is implanted).12,14,15 Therefore, the burden and risk of com-
plications related to PICCs are uncertain for patients undergoing
chemotherapy for acute leukemia and require further investigation.
Only a randomized controlled trial of the clinical application, safety,
and beneﬁt of using PICCs could resolve this important concern.
Thus, in the present open-label, randomized, monocentric, phase IV
study, we compared 2 different frontline approaches for CVCs (ie,
CICC vs. PICC) in patients with AML receiving intensive chemo-
therapy for hematologic remission induction.1-4
Patients and Methods
Trial Design
The patients were randomized 1:1 to receive a CICC (external,
nontunneled heparin-coated Vialon CVC; Becton-Dickinson,
Franklin Lakes, NJ) or PICC (open-ended, nonvalved pressure
injectable polyurethane PICC with a ﬂexible tip; EU-25541-HP
Arrow; Teleﬂex Medical, Westmeath, Ireland).
The random allocation sequence was performed using a
computerized system generated by the statistician’s study using the
procedure outlined in Supplemental Material 1 (available in the
online version).16 All patients were hospitalized in the Hematology
Unit of Federico II University (Naples, Italy). All CVCs were
implanted before chemotherapy began.
Implantation Procedures
External nontunneled CVCs (CICCs) were inserted by 3 of us
(intensive care medicine: N.P., M.R., F.C.), using the Seldinger
technique into the internal jugular or subclavian vein, according to
the clinical guidelines on central venous catheterization used in our
institution.17,18 These 3 physicians had had speciﬁc training in
central venous catheterization. All CICCs had been consistently
implanted using a strict antiseptic regimen with maximal barrier
precautions. Ultrasound (US) scanning was always used before
implantation to assess the anatomy of the target vein and adjacent
anatomic structures. When possible, US guidance was used. A chest
radiograph and echocardiography were routinely performed after
CICC application to conﬁrm the tip location.
All PICCs were inserted by medical hematology staff who had
been speciﬁcally trained in vascular access (M.P., R.D.P., F.T.,
C.M., C.G., I.Z.), with strict adoption of the GAVeCeLT (Gli
Accessi Venosi Centrali a Lungo Termine [Long-Term Central
Venous Access]) protocol for the safe insertion of PICCs (so-called
SIP protocol).12
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3601 Securement Device; TIDI Products, Neenah, WI). The
nurses strictly used the CVC policies in our hospital for dressing
changes, changes of the needle-free connector, ﬂushing the lumen
with a 0.9% sterile NaCl solution, and locking the lumen.
Antimicrobial prophylaxis with levoﬂoxacin and posaconazole
was performed before chemotherapy until neutrophil recovery.8 No
patient received prophylaxis with heparin. Patients with platelet
counts < 10,000/mL received concentrated platelet infusions before
catheter insertion.
Oversight
The present study was designed and planned in accordance with
the Declaration of Helsinki, October 2008 (59th World Medical
Association General Assembly, Seoul, Korea). All competent ethics
committees provided ethical approval, and all the patients provided
written informed consent. The present study was registered in the
ClinicalTrials.gov database (ClinicalTrials.gov identiﬁer,
NCT02405728).
Patients
The included patients were aged 18 years and had newly
diagnosed AML according to the World Health Organization
classiﬁcation system.19 Patients who had not previously received
systemic chemotherapy and/or radiotherapy were eligible. The pa-
tients were required to have the following clinical indications:
receipt of a cytotoxic agent regimen with an expected duration of
chemotherapy-induced aplasia of  7 days (for hematologic
remission induction)1-4 and an implanted CVC with an expected
use of  30 days.5,6 Patients with a suspected or conﬁrmed bac-
terial/fungal infection or thrombosis affecting the veins in the arms,
neck, or mediastinum were ineligible. In addition, patients with
acute promyelocytic leukemia, a diagnosis of other forms of cancer
within 12 months before AML onset, or any evidence of clinical
conditions indicating an inability to receive intent-to-cure chemo-
therapy, and those who did not provide written informed consent
were excluded from the present study.
Endpoints
The main endpoint was the cumulative incidence of catheter-
related (CR)-BSI and CR-VT, occurring from catheter insertion
until 30 days later. This composite endpoint was chosen speciﬁcally
to evaluate the safety of the primary implanted CVC and encom-
passed 2 possible outcomes. Each represented an early problem in
the induction chemotherapy phase to cure AML.7,8
The diagnosis of CR-BSI required either a differential time to
positivity of > 2 hours in a pair of central and peripheral blood
cultures (ie, the growth of microbes from a blood sample taken from
a central catheter hub  2 hours before microbial growth was
detected in a blood sample obtained from a peripheral vein) or the
detection of the same pathogen in a blood culture and at the
catheter tip. Either of these methods could be used as the diagnostic
criterion for the diagnosis of CR-BSI (Supplemental Material 2;
available in the online version).14
The diagnosis of CR-VT used objective criteria from US scans
(noncompressibility, absence of respiratory variation, and/or visu-
alization of a clear pericatheter thrombus [ie, a  0.5-cm echogenicintravascular mass extending from the CVC to the vessel wall]) and
clinical signs and symptoms (symptomatic thrombotic complica-
tion).7,8 Alternatively, CR-VT was detected only by systematic
screening with ultrasonography (using the objective US diagnostic
criteria listed) in the absence of clinical signs and symptoms
(asymptomatic thrombotic complication). Only cases of mural
thrombus on the vessel wall adjacent to the CVC that had partially
or completely occluded the vein in which the catheter resided were
included in the present study. The ﬁbroblastic sleeve was speciﬁcally
excluded.20 Additional data for the deﬁnition of CR-VT are pro-
vided in Supplemental Material 3 (available in the online version).
We have provided the rates of symptomatic thrombotic events
separately. Only these latter events and the CR-BSIs were consid-
ered clinically relevant CR major complications.18
The secondary endpoints were complications associated with
catheter positioning (serious bleeding, arterial puncture, and/or
pneumothorax), catheter malfunction (dislocation, occlusion, and/
or rupture), catheter removal, and overall mortality (Supplemental
Material 4; available in the online version).
Assessments
The patients were monitored for CR complications using the
same diagnostic evaluations for both groups. For BSI events, in the
case of neutropenic fever, 3 blood cultures obtained from both the
peripheral vein and the CVC were evaluated, along with conven-
tional clinical and laboratory assessments (Supplemental Material 5;
available in the online version).21 For thrombotic events, the veins
of the arm and cervicalethoracic areas were clinically assessed daily
by expert physicians (F.G., F.P.). In addition, the veins in the
ipsilateral side of catheter insertion routinely underwent US scan-
ning by 2 members of the catheter implantation staff (M.P. and
N.P., with > 10 years’ experience with color Doppler US) to rule
out subclinical VT, as previously reported (Supplemental Material
6; available in the online version).8
Treatment of CR-BSI and CR-VT
Cases of CR-BSI and/or CR-VT were managed in both groups in
accordance with international clinical guidelines.5,6,14 Antimicrobial
therapy and/or antithrombotic-speciﬁc therapy were given as pre-
viously reported.7,8 In the case of staphylococcus coagulase-negative
infection, we attempted to salvage the catheter with systemic anti-
biotic therapy. For all other pathogens associated with CR-BSI, the
device was promptly removed on microbiologic detection. Low-
molecular-weight heparin was introduced only for patients with a
platelet count of  20,000/mL.
Statistical Analysis
A power analysis was performed, with the assumption that BSI
and VT associated with CICCs would be detected in w50% of
patients with acute leukemia.7,8 In the case of PICC, the assump-
tion was that such complications would occur inw15% of patients
with acute leukemia.22 Superiority was predeﬁned as a difference in
the 30-day CR-BSI and CR-VT rate between the CICC and PICC
groups of  35 percentage points. Thus, a minimum sample of 44
patients in each group would be required to demonstrate superiority
at a 2-sided signiﬁcance level of 5% with 90% statistical power (a
error of 0.05 and b error of 0.9), corresponding to a relative riskClinical Lymphoma, Myeloma & Leukemia Month 2019 - 3
Figure 1 Flowchart Showing Patient Inclusion and Exclusion. *Atrial Fibrillation did not Allow Use Intracavitary Electrocardiographic
Guidance for Accurate Positioning of the Peripherally Inserted Central Catheter (PICC) tip; **Both Conditions, Detected by
Ultrasound Scans, Were Considered Contraindications to Implantation of ‡4 Fr PICC
Abbreviation: CICC ¼ centrally inserted central catheter.
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4 - Cli(RR) of 0.3. Because we assumed that 10% of patients would not be
included in the efﬁcacy analysis, we set an enrollment goal of  50
patients in each group (for 100 patients).
Continuous variables were compared using the Student t test for
normally distributed variables or the Mann-Whitney U test for non-
normally distributed variables. Categorical variables were evaluated
using the c2 or 2-tailed Fisher exact test. The RR and 95% con-
ﬁdence intervals (CIs) were calculated. The results are presented as
the median and range for the continuous variables or as percentages
of the group from which they were derived for the categorical
variables. Two-tailed t tests were used to determine statistical sig-
niﬁcance and P < .05 was considered statistically signiﬁcant. The
SPSS Statistics, version 22, program (IBM Corp., Armonk, NY)
was used.
Results
Patients
From April 1, 2015 through October 31, 2017, 100 adult patients
with untreated AML who had been referred to the hematology
department (Federico II University, Naples, Italy) were randomly
assigned to receive a CICC (standard group, n ¼ 50) or a PICC
(PICC group; n¼ 50). All randomized patients received the allocated
intervention, with the exception of 4 patients in the PICC group and
3 patients in the CICC group (standard group). No other patient was
lost to follow-up, nor did any patient withdraw consent to participate
in the present study during the follow-up period. Thus, the data from
93 patients (CICC group, n ¼ 47; PICC group, n ¼ 46) were
analyzed for the primary endpoint. Ten patients (9%) did not meet
the screening criteria. A ﬂowchart of the present study is shown in
Figure 1. The baseline characteristics of the analyzed patients were
well balanced between the 2 groups (Table 1).nical Lymphoma, Myeloma & Leukemia Month 2019CVC Positioning and Use
The characteristics and use of the catheters in both groups are
summarized in Table 2. In the CICC (standard) group, central
intravascular access was obtained through the subclavian vein in
w75% of patients. The most frequent catheter implanted was a 7Fr
device with a triple lumen. In the PICC group, central intravascular
access was obtained through the basilic vein in 89% of cases and the
most frequent catheter implanted was a 5 Fr device with a double
lumen. The ﬁrst insertion attempt success rates were similar in both
groups, showing the same expertise for both teams in CVC implan-
tation. The catheter tips were positioned between the lower third of
the superior vena cava and cavaeatrial junction in 100% of patients.
Chemotherapy infusions were administered through the CVC in
all the patients. No signiﬁcant differences were observed between
the 2 groups with regard to the cytarabine-containing induction
chemotherapeutic regimens. The median percentage of the received
dose intensity of the cytotoxic agents was 93% in the CICC group
and 94% in the PICC group. The durations of chemotherapy-
induced severe neutropenia (median, 15 days for the CICC
group; median, 16 days for the PICC group) and thrombocytopenia
(median, 10 days for the CICC group; median, 10 days for the
PICC group) were similar between the 2 groups.
Safety
After a median follow-up period of 30 days (range, 7-30 days), CR-
BSI and CR-VT complications, the primary endpoint, had developed
in 13% of patients in the PICC group and 49% of those in the CICC
group (6 of 46 vs. 23 of 47; RR, 0.266; 95%CI, 0.119-0.594; absolute
difference in risk, 0.359, 95% CI, 0.170-0.547; P ¼ .0003).
CR-BSI occurred in 2 patients in the PICC group and 11 in the
CICC group (4.3% vs. 23.4%; P ¼ .014). The incidence rate was
Table 1 Baseline Characteristics of Analyzed Patients
Characteristic All Patients CICC Group PICC Group P Value
Total patients 93 47 46
Sex .46
Male 47 (50.5) 22 (46.8) 25 (54.3)
Female 46 (49.5) 25 (53.2) 21 (45.7)
Age, years .64
Median 53.8 53 54.5
Range 18-80 18-74 24-80
Prothrombotic risk factors
BMI  25 kg/m2 12 (12.9) 7 (14.8) 5 (10.8) .20
Smoker 27 (29) 15 (31.9) 12 (26) .14
Hypertension 39 (41.9) 19 (40.4) 20 (43.4) .15
Diabetes 12 (12.9) 7 (14.8) 5 (10.8) .56
AML subtypea
AML with maturation 53 (56.9) 25 (53.2) 28 (60.8) .45
AML without maturation 16 (17.2) 10 (21.2) 6 (13) .29
AML with minimal differentiation 9 (9.6) 5 (10.6) 4 (8.7) .75
Acute myelomonocytic leukemia 6 (6.4) 3 (6.3) 3 (6.5) .98
Acute monoblastic/monocytic leukemia 5 (5.3) 2 (4.1) 3 (6.5) .63
Pure erythroid leukemia 2 (2.3) 1 (2.3) 1 (2.25) .98
Acute megakaryoblastic leukemia 2 (2.3) 1 (2.3) 1 (2.25) .98
Blood cell count
White blood cells, 103/mm3 .18
Median 3.4 3.2 3.9
Range 0.97-147 0.97-96 1.0-147
Hemoglobin, g/dL
Median 9.5 9.7 9.5
Range 5.9-12.6 5.9-12.1 6.6-12.6
Platelets, 103/mm3
Median 41 36 42.5
Range 3.0-275 3.0-275 9.0-232
Data presented as n (%) or median and range.
Abbreviations: AML ¼ acute myeloid leukemia; BMI ¼ body mass index; CICC ¼ centrally inserted central catheter; PICC ¼ peripherally inserted central catheter.
aAccording to the 2016 World Health Organization classiﬁcation of myeloid neoplasms and acute leukemia.14
Marco Picardi et al1.4 and 7.8/1000 catheters/d in the PICC and CICC groups,
respectively. The median interval between catheter insertion and
BSI episodes was 15 days (range, 8-23 days) for the PICC group and
7 days (range, 7-22 days) for the CICC group. The distribution of
causative pathogens is presented in Table 3. Coagulase-negative
staphylococci were the most frequently isolated pathogens.
CR-VT occurred in 4 patients in the PICC group and 12 patients
in the CICC group (8.7% vs. 25%; P ¼ .03). The incidence rate
was 2.9 and 8.5/1000 catheters/d in the PICC and CICC groups,
respectively. The median interval between catheter insertion and
thrombotic episodes was 10 days (range, 7-10 days) for the PICC
group and 7 days (range, 7-15 days) for the CICC group. Overall,
10 of 16 patients (60%) experienced CR asymptomatic thrombotic
events detected only by systematic US scans. The remaining patients
experienced CR symptomatic thrombotic complications (Table 3).
Thus, the rate of symptomatic VT was 2.1% in the PICC group
and 10.6% in the CICC group.During follow-up of the 13 patients with CR-BSI, 4 of the 11
patients (36%) in the CICC group developed septic thrombo-
phlebitis, ipsilateral to the catheter insertion site. The septic
thrombophlebitis was characterized by VT (conﬁrmed by US
scanning) with clinical features of inﬂammation (ie, pain, indura-
tion, erythema, exudates, and/or asymmetric venous distension).
For these 4 patients, the organisms responsible for infection were
multidrug-resistance strains and included Escherichia coli-producing
extended-spectrum b-lactamases (n ¼ 2), Klebsiella pneumoniae
carbapenemase-producing K. pneumoniae (n ¼ 1), and azole-
resistant Candida parapsilosis (n ¼ 1). In contrast, neither of the
2 patients with CR-BSI in the PICC group developed septic
thrombophlebitis.
Secondary Endpoints
Early mechanical complications associated with catheter posi-
tioning occurred in 13 patients (27.6%) in the CICC group (seriousClinical Lymphoma, Myeloma & Leukemia Month 2019 - 5
Table 2 Characteristics of Implanted Central Venous Catheters and Their Use
Characteristic All Patients CICC Group PICC Group
Total patients 93 (100) 47 (100) 46 (100)
Device insertion site
Basilic vein 41 (44) NA 41 (89.1)
Brachial vein 5 (5.4) NA 5 (10.9)
Subclavian vein 35 (37.6) 35 (74.5) NA
Internal jugular vein 12 (12.9) 12 (25.5) NA
Right side 70 (75.3) 37 (78.7) 33 (71.7)
Left side 23 (24.7) 10 (21.3) 13 (28.3)
Device type
Untunneled 93 (100) 47 (100) 46 (100)
4 Fr 14 (15) NA 14 (30.4)
5 Fr 29 (31.2) NA 29 (63)
6 Fr 3 (3.2) NA 3 (6.6)
7 Fr 35 (37.7) 35 (74.4) NA
8 Fr 12 (12.9) 12 (25.6) NA
Single lumen 14 (15) - 14 (30.4)
Double lumen 49 (52.6) 20 (42.5) 29 (63)
Triple lumen 30 (32.4) 27 (57.5) 3 (6.6)
Attempts at venipuncture, n
Median 1 1 1
Range 1-3 1-3 1-2
Tip locationa
Lower third of superior vena cava 23 (24.7) 13 (27.7) 10 (21.7)
Cavoeatrial junction 70 (75.3) 34 (72.3) 36 (78.3)
Reason for CVC
Sampling 83 (89.2) 42 (89.4) 41 (89.1)
Transfusion 75 (80.6) 35 (74.5) 40 (87.0)
Total parenteral nutrition 40 (43.0) 20 (42.6) 20 (43.5)
Antimicrobial agent 81 (87.1) 41 (87.2) 40 (87.0)
Chemotherapy 93 (100) 47 (100) 46 (100)
Induction course of EORTC-GIMEMA AML-10 regimenb 41(44.1) 21 (44.6) 20 (43.4)
Induction course of HOVON-SAKK regimenc 18 (19.4) 10 (21.3) 8 (17.4)
Induction course of FLAG-Ida regimend 24 (25.8) 11 (23.4) 13 (28.3)
Induction course of GIMEMA AML-12 regimene 10 (10.7) 5 (10.7) 5 (10.9)
Interval from CVC implantation to chemotherapy start, d
Median 1.5 1 1
Range 1-3 1-3 1-3
Chemotherapy-induced side effect
Severe neutropeniaf 93 (100) 47 (100) 46 (100)
Severe thrombocytopeniag 93 (100) 47 (100) 46 (100)
Data presented as n (%) or median and range.
Abbreviations: AML ¼ acute myeloid leukemia; CICC ¼ centrally inserted central catheter; CVC ¼ central venous catheter; EORTC ¼ European Organization for Research and Treatment of Cancer;
FLAG ¼ ﬂudarabine, cytarabine, granulocyte colony-stimulating factor; GIMEMA ¼ Gruppo Italiano Malattie Ematologiche dell’ Adulto; HOVON ¼ Hemato-Oncologie voor Valwassenen Nederland;
Ida ¼ idarubicin; NA ¼ not applicable; PICC ¼ peripherally inserted central catheter; SAKK ¼ Swiss Group Clinical Cancer Research.
aTip location was assessed by postprocedural chest radiograph and echocardiography in the CICC group and intraprocedural electrocardiography in the PICC group; the correct tip location was
between the lower third of the superior vena cava and the cavoeatrial junction.
bEORTC-GIMEMA AML-10 protocol: the schedule for the induction course was continuous intravenous infusion of cytarabine 100 mg/m2 daily for 10 days plus etoposide 100 mg/m2 daily by 1-hour
intravenous infusion on days 1-5 plus daunorubicin 50 mg/m2 daily as a 5-minute intravenous infusion (31 patients) or idarubicin 10 mg/m2 as a 5-minute intravenous infusion (5 patients) or
mitoxantrone 12 mg/m2 as a 30-minute intravenous infusion (5 patients) on days 1, 3, and 5.2
cHOVON-SAKK protocol: the schedule for the induction course was continuous intravenous infusion of cytarabine 200 mg/m2 daily for 7 days plus idarubicin 12 mg/m2 daily as a 3-hour intravenous
infusion on days 5-7.1
dFLAG-Ida protocol: the schedule for the induction course was cytarabine 2000 mg/m2 daily as a 3-hour intravenous infusion for 4 days plus ﬂudarabine 30 mg/m2 daily as a 30-min intravenous
infusion for 4 days plus idarubicin 12 mg/ m2 daily as a 1-hour intravenous infusion on days 2-4.3
eEORTC-GIMEMA AML-12 protocol: the schedule for the induction course was cytarabine 3000 mg/m2 every 12 hours as a 3-hour intravenous infusion on days 1, 3, 5, and 7 plus daunorubicin 50
mg/m2 daily as a 5-minute intravenous infusion on days 1, 3, and 5 plus etoposide 50 mg/m2 daily as a 1-hour intravenous infusion on days 1-5.4
fDeﬁned as neutrophil count < 500/mm3 with a duration of  7 days.
gDeﬁned as platelet count < 10,000/mm3 with a duration of  7 days.
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Table 3 Characteristics of Catheter-related Deep VTs and
BSIs
Characteristic
CICC Group
(n [ 47)
PICC Group
(n [ 46)
Catheter-related deep VTs
Events, n 12 4
Thrombosis symptoms/clinical signs
No 7 3
Yes 5 1
Ultrasound examinationsa
Baseline 47 46
þ3 days 46 46
þ7 days 42 46
þ15 days 35 44
þ23 days 29 40
þ30 days 21 36
Thrombolysed catheter size, Fr
5 0 4
7 7 0
8 5 0
Thrombus site
Basilic vein 0 3
Brachial vein 0 1
Axillary vein 6 2
Subclavian vein 7 0
Internal jugular vein 7 0
Brachiocephalic vein 6 0
Thrombosis in multiple sites 7 2
Thrombus size, mm
Median 20 20
Range 5-80 5-50
Platelet count,b 103/mm3
Median 40 35
Range 5-80 4-90
Prophylactic concentrated platelet infusion
Yes 15 13
No 32 33
Antithrombotic-speciﬁc therapyc
Yes 8 2
No 4 2
Catheter-related BSIs
Events, n 11 2
Causative pathogens
Gram-positive 6 2
Staphylococcus haemolyticus 2 2
Staphylococcus epidermidis 2 -
Staphylococcus aureus 1 -
Enterococcus spp. 1 -
MDR gram-positive bacteriad 4 1
Gram-negative 4 0
Escherichia coli 3 0
Klebsiella pneumoniae 1 0
Table 3 Continued
Characteristic
CICC Group
(n [ 47)
PICC Group
(n [ 46)
MDR gram-negative bacteriae 3 0
Candida parapsilosis f 1 0
WBC count,b 103/mm3
Median 0.2 0.1
Range 0.1-1 0.1-1
Antimicrobial prophylaxis
Levoﬂoxacin (oral 500 mg/d) 47 46
Posaconazole (oral 200 mg 3/d) 47 46
Data presented as number of patients or median and range.
Abbreviations: BSIs ¼ blood stream infections; CICC ¼ centrally inserted central catheter;
MDR ¼ multidrug resistance; PICC ¼ peripherally inserted central catheter; VTs ¼ venous
thromboses; WBC ¼ white blood cell.
aPatients who had undergone follow-up ultrasound scans at the scheduled time points.
bDeﬁned as platelet or WBC count at the thrombotic or infectious event, respectively.
cLow-molecular-weight heparin was introduced only for patients with a platelet count  20 
103/mm3.
dAmong the 8 patients with gram-positive infection, 5 had MDR bacteria (ie, methicillin-resistant
Staphylococcus spp. [4 cases in the CICC group and 1 in the PICC group]).
eAmong the 4 patients with gram-negative infection, 3 had MDR bacteria (ie, Escherichia coli-
producing extended-spectrum b-lactamases in 2 and Klebsiella pneumoniae carbapenemase-
producing K. pneumoniae in 1, all in the CICC group).
fAzole-resistant Candida parapsilosis.
Marco Picardi et albleeding in 7, arterial puncture in 5, and pneumothorax in 1)
compared with 2 patients (4%) in the PICC group (serious bleeding
in 1 and arterial puncture in 1; P ¼ .002).
Catheter malfunction occurred in 5 patients (10%) in the CICC
group (dislocation in 2, occlusion in 2, and rupture in 1) compared
with 4 patients (8.6%) in the PICC group (occlusion in 2, dislo-
cation in 1, and rupture in 1; P ¼ .7).
Sixteen patients (34%) in the CICC group required removal of
the device (median, 7 days after insertion). Removal was required
because of BSI in 5 patients (methicillin-resistant Staphylococcus
haemolyticus in 2, methicillin-resistant S. epidermidis in 1, S. aureus
in 1, and E. coli in 1), septic thrombophlebitis in 4 patients, VT in
2, and malfunction in 5 patients. In contrast, 6 patients (13%) in
the PICC group required catheter removal (median, 10 days after
insertion). The reason for removal was VT in 2 patients and mal-
function in 4 (P ¼ .017).
The 30-day overall mortality was 21% (10 of 47 patients) in the
CICC group. Death was from venous thromboembolism associated
with CICC in 4 patients and leukemia progression in 3, septic shock
associated with CICC in 2 patients (S. aureus in 1 and methicillin-
resistant S. haemolyticus in 1), and cerebral hemorrhage in 1 patient.
In contrast, the 30-day overall mortality was 8.6% (4 of 46 patients)
in the PICC group. Death was from leukemia progression in 2
patients, cerebral hemorrhage in 1 patient, and pulmonary asper-
gillosis in 1 patient (P ¼ .09).
Discussion
The choice of central venous access for frontline therapy in pa-
tients with acute leukemia has been controversial.1-6 The American
Society of Clinical Oncology and European Society for Medical
Oncology clinical practice guidelines have generally left the decision
of which device to use to the discretion of the treating physician.5,6Clinical Lymphoma, Myeloma & Leukemia Month 2019 - 7
Figure 2 Rates and Relative Risk of Primary and Secondary Endpoints
Abbreviations: BSI ¼ bloodstream infection; CI ¼ conﬁdence interval; CICC ¼ centrally inserted central catheter; CR ¼ catheter-related; PICC ¼ peripherally inserted central catheter; VT ¼ venous
thrombosis.
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been considered but should be accurately discussed with the pa-
tient.14 BSI and/or VT associated with intravascular devices are very
critical complications that can increase patient morbidity and
mortality during the initial phase of antileukemic treatment.7-11,14
To the best of our knowledge, the present study is the ﬁrst
comparative controlled randomized trial with an adequate sample
size providing clear evidence of the signiﬁcant beneﬁts of a PICC-
driven strategy compared with a CICC-driven strategy in the spe-
ciﬁc setting of patients with AML undergoing cytarabine-based
induction chemotherapy.1-4 The study objective of showing the
superiority of PICC versus CICC in terms of safety was achieved.
The rates of infection and thrombotic adverse events with a front-
line central venous approach using PICCs were signiﬁcantly lower
(36 percentage points less) than those using CICCs.
First, the CICC group had a 34% risk of CR-BSI and symp-
tomatic CR-VT compared with a 6.5% risk in the PICC group (16
of 47 vs. 3 of 46; RR, 0.197; 95% CI, 0.056-0.614; absolute dif-
ference in risk, 0.275; 95% CI, 0.113-0.424; P ¼ .0015). Thus,
PICC insertion corresponded to an approximately ﬁvefold reduc-
tion in risk of CR major complications compared with CICC
insertion during the ﬁrst 30-day catheter in situ follow-up period,
conﬁrming the beneﬁts of a PICC-driven strategy. Second,
approximately one third of the CICCs required early removal
mostly due to difﬁcult-to-treat infections. In contrast, approxi-
mately one tenth of the PICCs required removal and none was for
device infection. Thus, our PICC-driven strategy allowed an
approximately one quarter reduction in premature CVC removal
compared with the CICC-driven strategy. Third, the difference in
30-day overall mortality between the 2 groups was not statistically
signiﬁcant. However, when we considered only the deaths from CRnical Lymphoma, Myeloma & Leukemia Month 2019complications, the difference became statistically signiﬁcant. None
of the 4 deaths in the PICC group were associated with catheter-
related adverse events. In contrast, 6 of the 10 deaths (60%) in
the CICC group were associated with catheter-related adverse
events. These included venous thromboembolism as a complication
of septic thrombophlebitis in 4 patients and septic shock as a
complication of BSI in 2 patients. In all these patients, multidrug-
resistance pathogens were involved (P ¼ .012). Finally, for one half
of the secondary endpoints in the present trial, the comparison
showed signiﬁcant disadvantages for CICCs (Figure 2).
In our randomized study, we examined 2 different frontline ap-
proaches for central venous access, one using CICCs and one using
PICCs, in patients receiving induction chemotherapy for AML.1-4
We arbitrarily chose a composite primary endpoint of CR-BSI
and CR-VT because of the remarkable effect of these events on
daily clinical practice for patients with AML.7-11 The CICC was
selected as the standard approach for the present study and was
inserted in the hematology unit by a team of intensive care medicine
physicians especially trained in strict antiseptic regimens (with
maximal barrier precautions), US evaluations, and tip location
assessment, as described in the international guidelines.17,18 All
CICCs were secured with a sutureless device. Within our hospital,
the policy was to implant external nontunneled CICCs, preferably
in the subclavian vein, for ﬁrst-line short- to intermediate-term use,
especially for patients with newly diagnosed AML who required
urgent treatment.23 Skin-tunneled CICCs were reserved for those
patients scheduled to subsequently undergo stem cell rescue. Cen-
tral venous access using PICCs was selected as the experimental
group. We have highlighted the written procedures (collected and
reviewed before the start of enrollment) that deﬁned the PICC
insertion protocol.12,13,24 The protocol included bilateral US scans
Marco Picardi et alof all veins of the arm and neck before the procedure. In addition,
the appropriate vein at the upper mid-arm (“the green zone of the
zone insertion method”) chosen was the vein with a diameter in
millimeters on the US scan that was at least that of the catheter
diameter in French. Also, a clear identiﬁcation on the US scan of the
median nerve and brachial artery was required before venipuncture,
which was performed with US guidance. We also strictly performed
hand washing, an aseptic technique, and maximal barrier protec-
tion. An US scan of the internal jugular vein was also performed
during introduction of the catheter. Finally, we used an intracavitary
electrocardiographic method to assess the tip position and secured
the PICC with a sutureless device.12,13,22,24
When examining the reported studies, the data available from
cases of acute leukemia have suggested that PICCs confer an
increased risk of upper extremity VT and/or infection compared
with CICCs.7,9-11 However, all studies on this issue were retro-
spective, included patients at different phases of antileukemic
treatment (eg, consolidation or salvage treatment, transplantation
and, thus, undergoing second- or third-line central venous access),
and did not test the role of speciﬁc procedures (protocol) followed
by the implantation teams during and after catheter insertion.7,9-11
In the present trial, our protocol (detailed in the previous paragraph)
was strictly followed during the study period, which might have
contributed to the relatively low incidence of major adverse events
in the PICC-assisted patients. In contrast, in patients treated with
cytarabine-containing intensive regimens, a severe immunocom-
promised status, a profound tendency to hemostasis dysfunctions,
and poor wound-healing ability could represent factors that nega-
tively affect patients’ ability to tolerate a CICC.1-4 In such cases,
infection and thrombosis should not be considered separate entities,
given their bidirectional relationship.8,25 The mechanical trauma
intrinsically associated with subclavian catheter insertion means the
procedure is more invasive. Vein wall endothelial damage and/or
inﬂammatory mediator release contribute to thrombosis, creating a
more prothrombotic environment.8,12,14 Moreover, the skin of the
cervicalethoracic area will have been colonized by a diverse
collection of microorganisms, especially gram-positive bacteria.15 It
has been reported that 50 to 100 colony-forming units/10 cm2 will
be present on the skin of the middle third upper arm compared with
1000 to 10,000 colony-forming units/10 cm2 at the
cervicalethoracic area.13-15 We believe these ﬁndings might explain
the greater incidence amount and severity of CICC-associated in-
fectious and thrombotic events compared with those associated with
PICCs.
Our study had several limitations. First, it was a single-center
study with a small number of events, which limited the statistical
results. Hence, our ﬁndings should be validated in a prospective
large trial. Second, the clinical relevance of asymptomatic CR
thrombosis continues to be debate, and routine screening with
objective testing has not generally been recommended.7 In the
present study, the difference in the symptomatic CR-VT rates be-
tween the 2 groups (5 of 47 [10.6%] in the CICC group vs. 1 of 46
[2.1%] in the PICC group) was not statistically signiﬁcant (P ¼
.09). However, our decision to also study asymptomatic events was
determined by the consideration that therapy with low-molecular-
weight heparin is more effective in the presence of early throm-
bosis.26 Third, skin-tunneled CICCs have been reported to havesigniﬁcantly lower rates of VT and BSI compared with external
nontunneled CICCs.5,6,11,14 Fourth, for the clavicular vein
approach, US guidance will often not be feasible, increasing the
mechanical trauma intrinsically associated with CICC insertion.
Fifth, the choice of using heparin-coated CICCs might have facil-
itated staphylococcus infections,27 and the absence of an intra-
procedural tip location method in the CICC group might have
increased the risk of VT. Finally, we restricted our investigation to
pressure-injectable polyurethane PICCs. However, the
latest-generation polyurethane power-injectable PICCs have been
associated with a minor rate of adverse events, as previously reported
by others.28
Conclusion
The presented data have shown that the PICC is an easy-to-use
device that enables safe and effective central intravascular access for
patients receiving intensive chemotherapy for hematologic remission
induction of AML.1-4 In contrast, BSI and septic thrombophlebitis
emerged as life-threatening complications for neutropenic patients
with external nontunneled CICCs in situ.8 Our ﬁndings highlight
the importance of a team experienced in PICC positioning and care,
with a well-written protocol to optimize the catheter insertion
procedures and subsequent management.12,13,24 With optimal
conditions and experienced physicians, we propose the use of PICC
as a new frontline option for CVC29 in patients with acute leukemia
undergoing intensive chemotherapy.1-4
Clinical Practice Points
 PICCs provided superior safety compared with CICCs and
maintained effectiveness as primary central venous access for
patients undergoing chemotherapy for remission induction of
AML.
 We suggest this minimally invasive device as a new option for
frontline CVC in patients with acute leukemia.Supplemental Data
The supplemental data accompanying this article can be found in
the online version at https://doi.org/10.1016/j.clml.2018.12.008.References
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Supplemental Material 1
The random allocation sequence used a minimization method,16
in which the patients were assigned to 2 study groups using a
computerized system and ensuring equal distribution on the basis of
sex, age, body mass index, smoking history, hypertension, diabetes,
acute myeloid leukemia subtype, blood cell count at baseline, and
scheduled induction chemotherapy regimen.1-4
Supplemental Material 2
CR-BSIs were deﬁned using the Infectious Diseases Society of
America guidelines.14 Deﬁnite CR-BSI required either a differential
time to positivity > 2 hours in a pair of peripheral and central blood
cultures (ie, growth of microbes from a blood sample taken from a
central catheter hub  2 hours before microbial growth was
detected in a blood sample obtained from a peripheral vein) or the
detection of the same pathogen with the same susceptibility pattern
in a blood culture and at the catheter tip. We used either of these
methods as the diagnostic criterion for CR-BSI.
Supplemental Material 3
CR-VT was deﬁned as thrombus occurring acutely in the ipsi-
lateral side of device insertion and involving the deep veins of the
upper arm or cervicalethoracic area (ie, basilica, brachial, axillary,
subclavian, internal jugular, and/or brachiocephalic veins; all seated
ipsilateral to the catheter site).7,8 Ultrasound-detected thrombotic
episodes associated with CVC in the absence of speciﬁc clinical signs
and/or symptoms were considered events in our study. Thrombosis
was detected clinically (physical examination ﬁndings of pain,
induration, erythema, exudates, and/or asymmetric venous disten-
sion) and/or radiologically (US ﬁndings: noncompressibility,
absence of respiratory variation, and/or visualization of a clear
intraluminal thrombus [ie, a  0.5-cm echogenic pericatheter
intravascular mass]).7,8 Thrombotic events included mural throm-
bosis (the presence of a blood clot adhering to the vessel wall and
that could occlude the tip of the catheter but did not completely
occlude the vein in which the catheter was positioned; blood ﬂow
present on color Doppler; the thrombus was directly visualized,
and/or the vein was incompressible) and complete thrombosis (the
presence of a blood clot around the catheter that adhered to the
vessel wall and completely occluded the vein; the thrombus was
directly visualized, and/or the vein was incompressible; with no
blood ﬂow present on color Doppler).20 The presence of a ﬁbro-
blastic sleeve (ie, a cylinder image with well-deﬁned margins that
originated at the site of catheter insertion and ﬂuctuated within the
vessel lumen without creating an obstruction [fully compressible
vessel, with blood ﬂow present throughout the vascular section])
was not considered as thrombotic event.20Supplemental Material 4
Complications associated with catheter positioning were deﬁned
as serious bleeding (blood transfusion requirement), arterial
puncture, and/or pneumothorax (ie, the entry of air into the
pleural space as detected by chest radiography) during implanta-
tion of the central intravascular device.7 Catheter malfunction was
deﬁned as dislocation (>4 cm), occlusion (no infusion, no with-
drawal), and/or rupture of the catheter during the 30-day study
period.7 Overall mortality included death from any cause, from
catheter insertion until 30 days later. All deaths were reviewed by
an independent adjudication committee, which evaluated the
possibility of a relationship with the central venous catheter. In
particular, the following catheter-related fatal events were evalu-
ated: septic shock (systemic inﬂammatory response and  1 organ
dysfunction)14 and pulmonary embolism (conﬁrmed by the pres-
ence of a thrombus in a segmental or more proximal pulmonary
artery on computed tomography pulmonary angiography or
ventilation-perfusion scan).7,9Supplemental Material 5
For blood cultures, 10 mL of blood was analyzed (Sygnal System,
Oxoid, Hants, United Kingdom). The Vitek 2 automated system
(bioMérieux, Marcy l’Etoile, France) was used for blood stream
isolate identiﬁcation and antimicrobial susceptibility testing. Mini-
mum inhibitory concentrations were evaluated using E-test strips
(BioMerieux) and classiﬁed in accordance with the European
Committee on Antimicrobial Susceptibility Testing guidelines.
Blood isolates of multidrug-resistant Enterobacteriaceae spp., such as
Escherichia coli-producing extended-spectrum b-lactamases and
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae, or
methicillin-resistant Staphylococcus spp. were conﬁrmed using
adjunct microbiological tests.21Supplemental Material 6
All randomized patients were scheduled to undergo US scans
(including compression, B-mode imaging with the addition of co-
lor- and pulsed-wave Doppler) before and 3, 7, 15, 23, and 30 days
after CVC insertion, using an US scanner (iU22; Philips Health-
care, Bothell, WA) equipped with 9-3 and 12-5 MHz broadband
linear probes.8 The following US parameters were recorded on both
sides of the basilica, brachial, axillary, subclavian, internal jugular,
and/or brachiocephalic veins: venous vessel patency, presence or
absence of vein compressibility, echogenicity within the vein lumen,
characteristics of venous ﬂow, including the presence or absence of
cardiac pulsatility transmitted, and the response to respiratory ma-
neuvers.8 The US investigations were performed directly at the
patient’s bedside.Clinical Lymphoma, Myeloma & Leukemia Month 2019 - 10.e1
